ANGELES UNIVERSITY FOUNDATION

Angeles City
COLLEGE OF NURSING
===========================================================================================================================

NAME: DAVID, KHRISTLE RAIN M. ROTATION: OPD APU

GROUP AND SECTION: BSN 3B GROUP 5 AREA: JBLMH

GENERIC BRAND DRUG MECHANISM OF CONTRA- SIDE EFFECTS OR NURSING

STOCK DOSAGE INDICATIONS
NAME NAME CLASSIFICATION ACTION INDICATIONS ADVERSE REACTIONS INTERVENTIONS

Risperido Aspidon Risperidone, Risperidone, ● Oral Tablets: Risperidone Most common; BEFORE:
ne marketed as including its brand Typically (Aspidon OS) is ● Risperidone ● Drowsiness or ● Obtain a
Aspidon OS, falls name Aspidon OS, available in indicated for the (Aspidon) is sedation thorough
under the exerts its therapeutic strengths of treatment of contraindicated ● Weight gain medical
category of effects by 0.25 mg, 0.5 schizophrenia, in patients with ● Increased history,
atypical antagonizing mg, 1 mg, 2 moderate to a known appetite including
antipsychotic dopamine receptors mg, 3 mg, severe manic hypersensitivity ● Dizziness any
medications, in the brain, and 4 mg. episodes to the product. ● Restlessness or allergies,
primarily particularly the D2 associated with ● Hypersensitivity agitation previous
employed for receptors. By ● Oral bipolar disorders to the active ● Tremors or reactions
managing blocking dopamine Disintegratin and for short-term substance or to muscle stiffness to
psychiatric transmission, g Tablets treatment (up to 6 any of the ● Dry mouth medicatio
disorders like risperidone helps (ODT): weeks) of excipients such ● Constipation ns, and a
schizophrenia regulate Available in persistent as Benzoic acid ● Nausea history of
and bipolar neurotransmitter strengths of aggression in (E210) water, ● Elevated psychiatric
disorder. activity, alleviating 0.25 mg, 0.5 patients with purified. prolactin levels or
symptoms mg, 1 mg, 2 moderate to ● Risperidone leading to neurologic
associated with mg, 3 mg, severe Alzheimer's (Aspidon OS) potential breast al
psychiatric disorders and 4 mg. dementia should not be enlargement or disorders.
such as unresponsive to used more than lactation ● Assess
schizophrenia and ● Oral non-pharmacologic 6 weeks in the
bipolar disorder. Solution: al approaches and patients with Adverse Reaction patient's
Additionally, its Concentratio when there is a persistent ● Neuroleptic current
antagonistic action n may vary, risk of harm to self aggression in Malignant medicatio
on serotonin commonly or others. Alzheimer's Syndrome (NMS) ns,
receptors contributes available in dementia. - a rare but including
to its efficacy and 1 mg/mL or ● Not serious condition over-the-c
distinguishes it as an 2 mg/mL. recommended ● Tardive ounter
atypical antipsychotic in children less Dyskinesia - drugs and
with a unique ● Long-Acting than 5 years of involuntary herbal
mechanism Injectable age, as there is movements of suppleme
compared to older, (LAI) no experience the face and nts, to
typical antipsychotic Formulation: in children less body, potentially identify
medications. Available in than 5 years of irreversible potential
various age with this ● Metabolic interaction
strengths, disorder. changes, s with
such as 12.5 ● QT including an Risperido
mg, 25 mg, Prolongation: increased risk of ne.
37.5 mg, Contraindicated diabetes and ● Conduct a
and 50 mg in patients with high cholesterol psychiatric
for a history of QT levels assessme
intramuscula interval nt to
r injection. prolongation or understan
those taking d the
other patient's
medications mental
known to health
prolong the QT status
interval. ● Perform a
● Severe physical
Cardiovascular examinati
Disorders: on to
Contraindicated assess
in patients with the
recent patient's
myocardial overall
infarction or health,
heart failure, including
where an vital signs,
increased risk weight,
of adverse and any
cardiac events signs of
may exist. physical
● Central health
Nervous issues
System that may
Depression: impact the
Avoid use in use of
conditions Risperido
where central ne.
nervous system ● Perform a
depression neurologic
could be al
harmful, such assessme
 as alcohol nt and
intoxication or conduct
in the presence pregancy
of other central test for
nervous system woman.
depressants.
● Dementia-Relat DURING:
ed Psychosis in ● Verify the
Elderly prescribed
Patients: dose and
Contraindicated frequency
in elderly of
patients with Risperido
dementia-relate ne
d psychosis ● Educate
due to an the patient
increased risk about the
of mortality. purpose of
● Breastfeeding: Risperido
Contraindicated ne, its
in expected
breastfeeding effects,
women, as and
risperidone is potential
excreted in side
breast milk. effects or
The potential adverse
risks to the reactions.
infant should ● Discuss
be carefully the
considered. importanc
● Hyperprolactine e of
mia-Related medicatio
Conditions: n
Use with adherence
caution in and
conditions address
sensitive to any
changes in concerns
prolactin levels, or
such as breast questions
cancer, as the patient
risperidone may have.
may cause ● Administer
elevated Risperido
 prolactin levels. ne
● Elderly Patients according
with Dementia: to the
Use caution in prescribed
elderly patients route and
with dementia, technique
as there is an (e.g., oral
increased risk administra
of tion with
cerebrovascula or without
r adverse food).
events, ● Monitor
including vital signs,
stroke. before
and after
medicatio
n
administra
tion, as
some side
effects
may
impact
these
parameter
s.
● Assess for
immediate
reactions
● Assess for
any
neurologic
changes

AFTER:
● Monitor
the patient
closely for
any
immediate
adverse
reactions
or side
effects
and any
 mental
status
changes
● Assess for
extrapyra
midal
symptoms
(EPS),
including
tremors,
rigidity,
bradykine
sia, and
tardive
dyskinesia
● Provide
education
to the
patient
and their
caregivers
about the
expected
effects of
Risperido
ne and
potential
side
effects.
● Emphasiz
e the
importanc
e of
reporting
any
unusual or
severe
side
effects
promptly.
● Address
any
discomfort
or
concerns
 the patient
may have
related to
the
medicatio
n. Provide
emotional
support
and
reassuran
ce as
needed.
● Monitor
the
patient's
hydration
status and
encourage
an
adequate
fluid
intake
unless
contraindi
cated.
Address
any issues
related to
changes
in appetite
or
nutritional
intake.
● Implement
safety
measures
as
needed,
especially
if the
patient
experienc
es
drowsines
s,
dizziness,
or
changes
in
coordinati
on.